Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame	Description
Primary	All-Cause Mortality at 30 Days	30 days	The percentage of participants who die from any cause within 30 days of enrollment.
Primary	All-Cause Mortality at 90 Days	90 days	The percentage of participants who die from any cause within 90 days of enrollment.
Primary	Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours	48 hours ± 6 hours	The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
Secondary	Major Bleeding Events	48 hours, 7 days, 30 days, 90 days	Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
Secondary	Clinical Deterioration	48 hours, 7 days	Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
Secondary	6-Minute Walk Test (6MWT) Distance	30 days, 90 days	Change in walking distance from baseline (estimated) to follow-up. Minimal Clinically Important Difference (MCID) ≥30 meters.
Secondary	Post-VTE Functional Status (PVFS) Score	30 days, 90 days	Assessment of functional limitation due to VTE (Scale 0-5).
Secondary	Quality of Life (PEmb-QoL)	90 days	The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains: Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain). Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL). Work-related Problems (WP): Evaluates difficulties in performing work or school duties. Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness. Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease.
Secondary	Symptomatic PE Recurrence	90 days	Confirmed recurrent PE via CTPA or V/Q scan.
Secondary	ICU Length of Stay	From ICU admission to ICU discharge, assessed up to 30 days	Duration of intensive care unit stay during the index hospitalization
Secondary	Total Hospital Length of Stay	From hospital admission to hospital discharge, assessed up to 90 days	Duration of index hospitalization from emergency department admission to hospital discharge
Secondary	Total Medical Costs	Through 90 days	Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
Other	Biomarker Improvement (Troponin, BNP, D-Dimer)	48 hours, 7 days	Percentage reduction in cardiac biomarkers and D-Dimer levels.
Other	Daily Step Count	Continuous monitoring through 90 days	Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period. Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07603700/registered

API reference For AI assistants